Patents Assigned to MedImmune, LLC
  • Influenza hemagglutinin and neuraminidase variants
    Patent number: 9028838
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: March 4, 2013
    Date of Patent: May 12, 2015
    Assignee: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble
  • ANTIBODIES AGAINST AND METHODS FOR PRODUCING VACCINES FOR RESPIRATORY SYNCYTIAL VIRUS
    Publication number: 20150125479
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Application
    Filed: September 8, 2014
    Publication date: May 7, 2015
    Applicant: MEDIMMUNE, LLC
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, JoAnn Suzich
  • Swine influenza hemagglutinin variants
    Patent number: 9017694
    Abstract: The technology relates in part to modified influenza viruses useful for vaccine development. Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: October 4, 2012
    Date of Patent: April 28, 2015
    Assignee: MedImmune, LLC
    Inventors: Hong Jin, Zhongying Chen
  • STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS
    Publication number: 20150086544
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Application
    Filed: November 26, 2014
    Publication date: March 26, 2015
    Applicant: MEDIMMUNE, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Stabilized liquid anti-RSV antibody formulations
    Patent number: 8986686
    Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: March 24, 2015
    Assignee: MedImmune, LLC
    Inventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
  • Methods of producing influenza vaccine compositions
    Patent number: 8986705
    Abstract: Methods and compositions for the optimization of production of influenza viruses suitable as influenza vaccines are provided.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: March 24, 2015
    Assignee: MedImmune, LLC
    Inventors: George Robert Trager, Vu Truong-Le, Luisa Yee
  • Methods of diagnosing and treating pulmonary diseases or disorders
    Patent number: 8961965
    Abstract: The present disclosure provides methods of diagnosing a subject as having a pulmonary disease or disorder, e.g., an eosinophilic disease or disorder based on the determination of white blood cell ratios. The disclosure also provides white blood cell ratio-based methods of treating, prognosing, or monitoring a pulmonary disease or disorder, as well as methods of methods of predicting a dosage regimen, identifying a candidate therapeutic agent, identifying a patient as a candidate for a therapeutic agent, and methods of designing a personalized therapy.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: February 24, 2015
    Assignee: MedImmune, LLC
    Inventors: David L Gossage, Deepak B. Khatry, Gregory P. Geba, Nestor Molfino, Joseph M. Parker
  • INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS AND USES THEREOF
    Publication number: 20150044222
    Abstract: The present invention encompasses type-I IFN and IFN?-induced PD marker expression profiles, kits, and methods for identifying such IFN?-induced PD marker expression profiles. The type-I IFN and IFN?-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFN?-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFN? activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFN? activity, and in diagnosing or providing a prognosis to patients having IFN?-induced disorders.
    Type: Application
    Filed: July 14, 2014
    Publication date: February 12, 2015
    Applicant: MEDIMMUNE, LLC
    Inventors: Yihong YAO, Bahija JALLAL, Ricardo CIBOTTI, Anthony COYLE, Peter KIENER
  • MOLECULES WITH EXTENDED HALF-LIVES, COMPOSITIONS AND USES THEREOF
    Publication number: 20140377181
    Abstract: The present invention provides molecules, including IgGs, non-IgG immunoglobulins, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, MEDIMMUNE, LLC
    Inventors: William Dall'Acqua, Leslie S. Johnson, Elizabeth Sally Ward Ober
  • BINDING MOLECULES SPECIFIC FOR HER3 AND USES THEREOF
    Publication number: 20140363429
    Abstract: The present invention relates to antibodies and antigen binding fragments thereof that bind the extracellular domain of the HER3 receptor and inhibit various HER3 receptor related functions via ligand-dependent and/or ligand-independent mechanisms. Also provided are compositions with increased half-life. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER3 mediated signal transduction.
    Type: Application
    Filed: November 20, 2012
    Publication date: December 11, 2014
    Applicant: MedImmune LLC
    Inventors: Partha S. Chowdhury, David Tice, Zhan Xiao, Philipp Steiner, Krista Kinneer, Marlon Rebelatto
  • Humanized anti-CD19 antibodies
    Patent number: 8883992
    Abstract: Isolated nucleic acids encoding anti-CD19 mouse monoclonal antibodies are described herein. Also described are expression vectors, host cells and a method of producing anti-CD19 antibodies.
    Type: Grant
    Filed: October 26, 2012
    Date of Patent: November 11, 2014
    Assignee: Medimmune, LLC
    Inventors: Melissa Damschroder, Peter Kiener, Herren Wu, William Dall'Acqua, Ronald Herbst, Anthony Coyle
  • Influenza hemagglutinin and neuraminidase variants
    Patent number: 8877210
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: November 4, 2014
    Assignee: MedImmune, LLC
    Inventors: Chin-Fen Yang, George Kemble, Chongguang Liu
  • METHODS FOR PROCESSING COAGULATION FACTORS
    Publication number: 20140303353
    Abstract: The present application relates to methods for purifying recombinant coagulation factor proteins, including for example, prothrombin (Factor II). In embodiments, the methods provide purified prothrombin that exhibit increased bioactivity and reduced levels of thrombin, thereby increasing the safety of the prothrombin. Also provided are purified recombinant coagulation factor proteins.
    Type: Application
    Filed: August 31, 2012
    Publication date: October 9, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Alan Hunter, Xiangyang Wang, Timothy Pabst, Michaela Wendeler, Jihong Wang, Kendall Carey, Robert Strouse, Johnson Varghese
  • HUMAN ANTI IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-LIFE AND THEIR USE IN TREATMENT OF ONCOLOGY, AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
    Publication number: 20140302058
    Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 9, 2014
    Applicant: MedImmune, LLC
    Inventors: Michael Bowen, Herren Wu, William Dall'Acqua, Peter Kiener, Bahija Jallal, Anthony Coyle
  • Antibodies against and methods for producing vaccines for respiratory syncytial virus
    Patent number: 8852608
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: October 7, 2014
    Assignee: MedImmune, LLC
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, Joann Suzich
  • MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
    Patent number: 8846032
    Abstract: The present invention relates to novel MDCK cells which can be to grow viruses, e.g., influenza viruses, in cell culture to higher titer than previously possible. The MDCK cells can be adapted to serum-free culture medium. The present invention further relates to cell culture compositions comprising the MDCK cells and cultivation methods for growing the MDCK cells. The present invention further relates to methods for producing influenza viruses in cell culture using the MDCK cells of the invention.
    Type: Grant
    Filed: August 27, 2012
    Date of Patent: September 30, 2014
    Assignee: MedImmune, LLC
    Inventors: Jonathan Liu, Richard Schwartz, Mark Thompson, Luis Maranga, Mridul Ghosh, Ajit Subramanian, Simon Sheng-Tsiung Hsu
  • HSA-RELATED COMPOSITIONS AND METHODS OF USE
    Publication number: 20140248682
    Abstract: Provided are human serum albumin (HSA) compositions with improved properties over native HSA.
    Type: Application
    Filed: February 14, 2014
    Publication date: September 4, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Changshou GAO, Chaity CHAUDHURY, Xiaotao YAO
  • INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS
    Publication number: 20140242102
    Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.
    Type: Application
    Filed: January 15, 2014
    Publication date: August 28, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Chin-Fen YANG, George KEMBLE, Chongguang LIU
  • DOSING REGIMENS FOR TREATMENT OF CEA-EXPRESSING CANCERS
    Publication number: 20140242081
    Abstract: The present disclosure provides compositions and methods for treating CEA-expressing cancers. Methods for dosing a patient with an antibody that binds to CEA and human CD3 are also provided.
    Type: Application
    Filed: July 18, 2011
    Publication date: August 28, 2014
    Applicants: MICROMET AG, MEDIMMUNE, LLC
    Inventors: Scott Hammond, Patricia Ryan, Song Ren, Petra Lutterbuese, Maria Amann
  • ANTI-PSEUDOMONAS PSL BINDING MOLECULES AND USES THEREOF
    Publication number: 20140227285
    Abstract: The disclosure relates to an anti-Pseudomonas PSL binding molecule and uses thereof, in particular, in prevention and treatment of Pseudomonas infection. Furthermore, the disclosure provides compositions and methods for preventing and treating Pseudomonas infection.
    Type: Application
    Filed: June 8, 2012
    Publication date: August 14, 2014
    Applicant: MEDIMMUNE, LLC
    Inventors: Antonio Digiandomenico, Paul G. Warrener, Charles K. Stover, Brett Sellman, Sandrine Gullard, Ralph Minter, Steven Rust, Mladen Tomich